Payment overview · 2025
General Payments
$490.04
28 reported records · 9 companies
Healthcare provider profile · identity verified
Mark Jeffery Mcnabb, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE GIRARDEAU, MO · NPI 1942337522
Verified facts
What the public records show
CMS Open Payments records show Mark Jeffery Mcnabb, D.O. received $490.04 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.16 | 32.9% | 9 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $90.57 | 18.5% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $76.39 | 15.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.48 | 11.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.53 | 6.8% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.12 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.00 | 4.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.74 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.05 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $490.04 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.41 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $90.57 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $76.39 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.14 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.77 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
349 | 52 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
223 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 741 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 672 | 126 |
| Valsartan | Valsartan | 491 | 99 |
| Montelukast Sodium | Montelukast Sodium | 487 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 427 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 401 | 84 |
| Synthroid | Levothyroxine Sodium | 349 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 53 |
| Losartan Potassium | Losartan Potassium | 298 | 51 |
| Alprazolam | Alprazolam | 284 | 49 |
| Tramadol Hcl | Tramadol Hcl | 270 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 46 |
| Donepezil Hcl | Donepezil Hcl | 239 | 37 |
| Lisinopril | Lisinopril | 239 | 53 |
| Metformin Hcl Er | Metformin Hcl | 231 | 60 |
| Eliquis | Apixaban | 223 | 30 |
| Simvastatin | Simvastatin | 209 | 41 |
| Omeprazole | Omeprazole | 203 | 35 |
| Sertraline Hcl | Sertraline Hcl | 198 | 37 |
| Gabapentin | Gabapentin | 173 | 35 |
| Ozempic | Semaglutide | 172 | 24 |
| Potassium Chloride | Potassium Chloride | 171 | 33 |
| Alendronate Sodium | Alendronate Sodium | 169 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 24 |
| Carvedilol | Carvedilol | 157 | 27 |
| Jardiance | Empagliflozin | 157 | 20 |
| Memantine Hcl | Memantine Hcl | 151 | 24 |
| Celecoxib | Celecoxib | 144 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 25 |
| Meloxicam | Meloxicam | 138 | 31 |
| Furosemide | Furosemide | 136 | 29 |
| Allopurinol | Allopurinol | 129 | 26 |
| Lorazepam | Lorazepam | 124 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 17 |
| Candesartan Cilexetil | Candesartan Cilexetil | 102 | 17 |
| Spironolactone | Spironolactone | 90 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 19 |
| Pregabalin | Pregabalin | 88 | 12 |
| Clonazepam | Clonazepam | 86 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 85 | suppressed |
| Xarelto | Rivaroxaban | 85 | 14 |
| Temazepam | Temazepam | 84 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 14 |
| Eszopiclone | Eszopiclone | 71 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 15 |
| Prednisone | Prednisone | 66 | 22 |
| Methylprednisolone | Methylprednisolone | 65 | 56 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 64 | suppressed |
| Entresto | Sacubitril/Valsartan | 63 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 60 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 13 |
| Ezetimibe | Ezetimibe | 56 | 14 |
| Famotidine | Famotidine | 53 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 51 | 51 |
| Torsemide | Torsemide | 50 | 11 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Ramipril | Ramipril | 41 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Sucralfate | Sucralfate | 35 | 12 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | 13 |
| Cartia Xt | Diltiazem Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 17 |
| Cephalexin | Cephalexin | 20 | 13 |
| Nabumetone | Nabumetone | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $490.04 · 28 records | ABBVIE INC. | Dexcom G6 Transmitter, FARXIGA, MOUNJARO, NURTEC ODT, Ohtuvayre, Omnipod, QULIPTA, REXULTI, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error